JP2009516155A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009516155A5 JP2009516155A5 JP2008532651A JP2008532651A JP2009516155A5 JP 2009516155 A5 JP2009516155 A5 JP 2009516155A5 JP 2008532651 A JP2008532651 A JP 2008532651A JP 2008532651 A JP2008532651 A JP 2008532651A JP 2009516155 A5 JP2009516155 A5 JP 2009516155A5
- Authority
- JP
- Japan
- Prior art keywords
- substance
- peptide
- protein
- organism
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims 40
- 239000000126 substance Substances 0.000 claims 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims 21
- 102000004169 proteins and genes Human genes 0.000 claims 18
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 229940123464 Thiazolidinedione Drugs 0.000 claims 16
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 238000010183 spectrum analysis Methods 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 7
- 102100029009 High mobility group protein HMG-I/HMG-Y Human genes 0.000 claims 6
- 101000986380 Homo sapiens High mobility group protein HMG-I/HMG-Y Proteins 0.000 claims 6
- 101100046559 Mus musculus Tnfrsf12a gene Proteins 0.000 claims 6
- 102000018746 Apelin Human genes 0.000 claims 5
- 108010052412 Apelin Proteins 0.000 claims 5
- BWVPHIKGXQBZPV-QKFDDRBGSA-N apelin Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCSC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 BWVPHIKGXQBZPV-QKFDDRBGSA-N 0.000 claims 5
- 108010016731 PPAR gamma Proteins 0.000 claims 4
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- QFYXSLAAXZTRLG-UHFFFAOYSA-N pyrrolidine-2,3-dione Chemical compound O=C1CCNC1=O QFYXSLAAXZTRLG-UHFFFAOYSA-N 0.000 claims 3
- 238000000926 separation method Methods 0.000 claims 3
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 150000001467 thiazolidinediones Chemical class 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims 1
- ORZMUVMQJPGFOM-UHFFFAOYSA-N 5-[(2,4-dioxo-1,3-oxazolidin-5-yl)methyl]-2-methoxy-n-[[4-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound C1=C(C(=O)NCC=2C=CC(=CC=2)C(F)(F)F)C(OC)=CC=C1CC1OC(=O)NC1=O ORZMUVMQJPGFOM-UHFFFAOYSA-N 0.000 claims 1
- ZNLPWBJCSSSCCR-UHFFFAOYSA-N 5-[3-[3-(4-phenoxy-2-propylphenoxy)propoxy]phenyl]-1,3-thiazolidine-2,4-dione Chemical compound C=1C=C(OCCCOC=2C=C(C=CC=2)C2C(NC(=O)S2)=O)C(CCC)=CC=1OC1=CC=CC=C1 ZNLPWBJCSSSCCR-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 102000000536 PPAR gamma Human genes 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 210000001789 adipocyte Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 claims 1
- 229950009226 ciglitazone Drugs 0.000 claims 1
- QQKNSPHAFATFNQ-UHFFFAOYSA-N darglitazone Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCC(=O)C(C=C1)=CC=C1CC1SC(=O)NC1=O QQKNSPHAFATFNQ-UHFFFAOYSA-N 0.000 claims 1
- 229950006689 darglitazone Drugs 0.000 claims 1
- 238000000432 density-gradient centrifugation Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- ZZCHHVUQYRMYLW-HKBQPEDESA-N farglitazar Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCC=1N=C(OC=1C)C=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 ZZCHHVUQYRMYLW-HKBQPEDESA-N 0.000 claims 1
- 229950003707 farglitazar Drugs 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000004817 gas chromatography Methods 0.000 claims 1
- 238000001502 gel electrophoresis Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000004811 liquid chromatography Methods 0.000 claims 1
- 239000007791 liquid phase Substances 0.000 claims 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229960005095 pioglitazone Drugs 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 229960004586 rosiglitazone Drugs 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000004809 thin layer chromatography Methods 0.000 claims 1
- 229960001641 troglitazone Drugs 0.000 claims 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- -1 valaglitazone Chemical compound 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05021530A EP1876448A1 (en) | 2005-09-30 | 2005-09-30 | Method and analytical reagents for identifying therapeutics using biomarkers responsive to thiazolidinediones. |
| PCT/EP2006/009324 WO2007039184A2 (en) | 2005-09-30 | 2006-09-26 | Method and analytical reagents for identifying therapeutics using biomarkers responsive to thiazolidinediones |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009516155A JP2009516155A (ja) | 2009-04-16 |
| JP2009516155A5 true JP2009516155A5 (enExample) | 2009-11-12 |
Family
ID=37114604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008532651A Withdrawn JP2009516155A (ja) | 2005-09-30 | 2006-09-26 | チアゾリジンジオン反応性バイオマーカーを用いる治療物質の同定法 |
Country Status (4)
| Country | Link |
|---|---|
| EP (2) | EP1876448A1 (enExample) |
| JP (1) | JP2009516155A (enExample) |
| CA (1) | CA2623685A1 (enExample) |
| WO (1) | WO2007039184A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8673848B2 (en) | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
| KR20100053607A (ko) | 2007-08-03 | 2010-05-20 | 패시트 바이오테크 코포레이션 | 항-ｔｗｅａｋ 수용체 항체의 치료 용도 |
| ES2373625T3 (es) * | 2007-12-19 | 2012-02-07 | Eli Lilly & Company | Procedimiento para predecir la sensibilidad a una terapia farmacéutica para la obesidad. |
| US10519504B2 (en) * | 2009-05-11 | 2019-12-31 | Berg Llc | Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
| EP2694463B8 (en) | 2011-04-04 | 2019-10-09 | Berg LLC | Treating central nervous system tumors with coenzyme q10 |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| US8921307B2 (en) | 2012-11-20 | 2014-12-30 | Novartis Ag | Synthetic linear apelin mimetics for the treatment of heart failure |
| EA032775B1 (ru) | 2013-04-08 | 2019-07-31 | Берг Ллк | Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10 |
| SG11201600211XA (en) | 2013-07-25 | 2016-02-26 | Novartis Ag | Cyclic polypeptides for the treatment of heart failure |
| TW201518323A (zh) | 2013-07-25 | 2015-05-16 | Novartis Ag | 合成ａｐｅｌｉｎ多肽之生物結合物 |
| WO2015035094A1 (en) | 2013-09-04 | 2015-03-12 | Berg Llc | Methods of treatment of cancer by continuous infusion of coenzyme q10 |
| WO2017087576A1 (en) | 2015-11-16 | 2017-05-26 | Berg Llc | Methods of treatment of temozolomide-resistant glioma using coenzyme q10 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1015477T3 (da) * | 1997-05-30 | 2011-02-07 | Human Genome Sciences Inc | 32 humane sekreterede proteiner |
| US7495086B2 (en) * | 1999-12-20 | 2009-02-24 | Immunex Corporation | TWEAK receptor |
| AU782067B2 (en) * | 1999-12-20 | 2005-06-30 | Immunex Corporation | TWEAK receptor |
| EP1287030A1 (en) * | 2000-06-08 | 2003-03-05 | Metcon Medicin AB | Insulin regulated substance (irs-2) induced by pioglitazone, assay and use thereof |
| US20050084872A1 (en) * | 2003-01-24 | 2005-04-21 | Lum Pek Y. | Methods for determining whether an agent possesses a defined biological activity |
| EP1566636A1 (en) * | 2004-02-23 | 2005-08-24 | AXARON Bioscience AG | Use of Tweak modulators and inhibitors for the treatment of neurological conditions |
-
2005
- 2005-09-30 EP EP05021530A patent/EP1876448A1/en not_active Withdrawn
-
2006
- 2006-09-26 WO PCT/EP2006/009324 patent/WO2007039184A2/en not_active Ceased
- 2006-09-26 JP JP2008532651A patent/JP2009516155A/ja not_active Withdrawn
- 2006-09-26 EP EP06792269A patent/EP1929309A2/en not_active Withdrawn
- 2006-09-26 CA CA002623685A patent/CA2623685A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fujinami et al. | Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes | |
| US8871527B2 (en) | Method and system for measuring a sample to determine the presence of and optionally treat a pathologic condition | |
| JP2009516155A5 (enExample) | ||
| CN105974123A (zh) | 与糖尿病前期、糖尿病及糖尿病相关病症相关的生物标记 | |
| KR20020097236A (ko) | 타입-2 당뇨병, 내당능 장애, 또는 공복 혈당 장애에 대한감수성을 검출하기 위한 위억제성 폴리펩티드 진단 시험 | |
| JP6465923B2 (ja) | 膵臓β細胞障害における可溶性ＭＡＮＦ | |
| AU2011258462A1 (en) | Methods of determining Amyloid beta turnover in blood | |
| Pendharkar et al. | Calcitonin gene-related peptide: neuroendocrine communication between the pancreas, gut, and brain in regulation of blood glucose | |
| Oberauer et al. | EGFL6 is increasingly expressed in human obesity and promotes proliferation of adipose tissue-derived stromal vascular cells | |
| EP3271730B1 (en) | Novel marker for gestational diabetes | |
| JP2024037767A (ja) | 改変型線維芽細胞成長因子２１（ｆｇｆ－２１）を用いる非アルコール性脂肪性肝炎（ｎａｓｈ）の処置方法 | |
| US20100210541A1 (en) | Biomarkers for Appetite Regulation | |
| US20230393148A1 (en) | Kits, reagents and methods for the assessment of liver diseases | |
| Sakuta et al. | Adiponectin levels and cardiovascular risk factors in Japanese men with type 2 diabetes | |
| CN117417427B (zh) | 一种检测内源性自体胰岛素介导的胰岛素抗体的试剂盒 | |
| JP2005528921A5 (enExample) | ||
| CN117447578B (zh) | 一种核糖体蛋白s26抗体的检测试剂盒 | |
| CN1928556A (zh) | 中国人2型糖尿病血清标志物的检测试剂盒 | |
| US20190033324A1 (en) | Process for In Vitro Diagnosis of Hepatic Disorders | |
| CN117434270B (zh) | 一种可携带放射性信号的蛋白质支架及其抗体检测中的应用 | |
| EP2626704A1 (en) | Diagnosis and complication risk assessment of pancreatic diabetes within normal value ranges of leucocytes using procalcitonin | |
| Fan et al. | Comparative analysis of serum proteins from patients with severe and mild EV‐A71‐induced HFMD using iTRAQ‐coupled LC‐MS/MS screening | |
| Al-Dujaili et al. | ASSESSMENT OF VASPIN AND RISK FACTORS IN RELATION WITH DIABETIC MELLITUS TYPE II | |
| CN119464479A (zh) | 预测或判断klk1蛋白在艾塞那肽治疗2型糖尿病效果的生物标志物及其应用 | |
| Lin et al. | Dynamics of plasma fibrinogen unveils hepatic initiating role in MS pathogenesis |